JNJ - J&J mid-stage trial for Tremfya against immune disorder fails
2024-06-25 15:03:18 ET
More on Johnson & Johnson
- Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
- Johnson & Johnson: Market Will Regret The Overreaction
- Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript)
- Johnson & Johnson closes acquisition of biotechnology company Proteologix
- J&J applies for FDA approval of Tremfya for Crohn's disease